Source-grounded facts extracted from Entera Bio Ltd.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Entera Bio Ltd. reported financial results for three months ended March 31, 2026.
“Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported financial results and key business updates for the quarter ended March 31, 2026.”
Entera Bio Ltd. entered into Purchase Agreement with funds affiliated with BVF Partners LP valued at approximately $10.0 (effective 2026-04-01).
“On April 1, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with funds affiliated with BVF Partners LP (collectively, the “ Purchaser ”), providing for the private placement (the “ Private Placement ”) to the Purchaser of an aggregate of 7,827,789 units (collectively, the “ Units ”), each Unit consisting of (i) one ordinary share, par value NIS 0.0000769 per share, of the Company (an “ Ordinary Share ”) (or, in lieu thereof, one pre-funded warrant to purchase one Ordinary Share (the “ Pre-Funded Warrants ”)) and (ii) one warrant to purchase one and a half Ordinary Shares (the “ Ordinary Share Warrant ”), for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).”
Entera Bio Ltd. reported financial results for the year ended December 31, 2025.
“On March 27, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the year ended December 31, 2025 and business updates.”
Entera Bio Ltd. amended Amended and Restated Collaboration and License Agreement with OPKO Health, Inc. and OPKO Biologics Ltd. (effective 2026-02-03).
“On February 3, 2026, the Company and OPKO entered into an amended and restated collaboration and license agreement (the “ A&R Collaboration Agreement ”), which amends and restates the Original Collaboration Agreement to expand the scope of the agreement to include the collaboration with respect to the preclinical and clinical development of a daily long acting PTH tablet (“ LA-PTH ”) for the treatment of hypoparathyroidism and other indications in addition to the original oral dual agonist GLP-1/glucagon peptide program .”
Entera Bio Ltd. reported the quarter ended March 31, 2024 results: net income $2.0 million, EPS $0.05 per ordinary share (basic and diluted).
“Net loss was $2.0 million, or $0.05 per ordinary share (basic and diluted), for the period ended March 31, 2024, as compared to $2.2 million, or $0.08 per ordinary share (basic and diluted), for the period ended March 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.